Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 5/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.35 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.32 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.32 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16154652 | 0.86 | CCR4 (0.41) | CCR4BRD4RORCSSTR4NR3C2 | |
| SCHEMBL19788942 | 0.86 | CCR4 (0.37) | CCR4BRD4RORCSSTR4KAT2B | |
| SCHEMBL19788938 | 0.85 | CCR4 (0.40) | CCR4RORCSSTR4SMN1; SMN2LMNA | |
| SCHEMBL24142870 | 0.82 | BRD4 (0.46) | CCR4BRD4SSTR4BRDTSMN1; SMN2 | |
| SCHEMBL24998325 | 0.81 | CCR4 (0.37) | CCR4BRD4SSTR4KAT2B | |
| SCHEMBL24998625 | 0.81 | RORC (0.33) | BRD4RORCNR3C2PSIP1 | |
| SCHEMBL25639319 | 0.80 | CDC7 (0.31) | — | |
| SCHEMBL16154727 | 0.79 | POLB (0.36) | CCR4SSTR4SMN1; SMN2KAT2BLMNA | |
| SCHEMBL19788722 | 0.79 | SSTR4 (0.35) | CCR4SSTR4KAT2B | |
| SCHEMBL19788939 | 0.77 | CCR4 (0.39) | CCR4BRD4RORCSSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312567-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11680064-B2 | Capsid inhibitors for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20230038823-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312567-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | HAVCR2, MAVS, CD4 | CCR4 311/4885BRD4 1037/4885RORC 702/4885 |
| US-20230038823-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | HAVCR2, MAVS, CD4 | CCR4 311/4885BRD4 1037/4885RORC 702/4885 |
| US-11680064-B2 | Capsid inhibitors for the treatment of HIV | HAVCR2, MAVS, CD4 | CCR4 311/4885BRD4 1037/4885RORC 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.